Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

All Drugs and Chemicals

Antineoplastic Agents

Amino Acids

Mitogens

Tyrosine Kinase Inhibitors

Erlotinib Hydrochloride

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day) with concurrent radiotherapy to a total radiation dose of 60-66 Gray (Gy).

Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day).

Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®)

Concurrent radiotherapy total dose 60-66 Gy in 2 Gy fractions. One fraction per day, and 5 fractions per week.

Radiotherapy

Zhishuang Zheng, Dr

Zhishuang Zheng

Shixiu Wu, MD

Concurrent chemoradiotheray is the standard care for patients with locally advanced non-small cell lung cancer (NSCLC), but often accompanying with high toxicity and poor tolerability. Radiosensitization of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) has been proved in preclinical studies, and the safety of TKI combined with thoracic radiotherapy has also been evaluated in several phase II trials. The aim of study is to investigate the efficacy and safety of thoracic radiotherapy combined with TKI in wild-type EGFR patients who refused or unsuitable for concurrent chemoradiotherapy.

RT Plus EGFR-TKI for Wild-type NSCLC

Thoracic Radiotherapy Combined With EGFR-TKI for Wild-type Non-small Cell Lung Cancer

Toxicity of the treatment will be evaluated according to the common toxicity criteria for adverse events version 3.0 (CTCAE v3.0).

Progression-free survival (PFS) will be calculated from the date of treatment initiation to the date of documented failure (local recurrence or metastasis occurrence) or the date of the last follow-up for those remaining.

Overall survival (OS) wiil be determined as the time (in months) between the first day of therapy and the last follow-up or the date of death.

Hangzhou Cancer Hospital

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
RT Plus EGFR-TKI for Wild-type NSCLC	NCT02738983	Non-small Cell ... Epidermal Growt...	Erlotinib (trad... Radiotherapy	19 Years -	Hangzhou Cancer Hospital
RT Plus EGFR-TKI for Wild-type NSCLC	NCT02738983	Non-small Cell ... Epidermal Growt...	Erlotinib (trad... Radiotherapy	19 Years -	Hangzhou Cancer Hospital

Spots Global Cancer Trial Database for erlotinib (trade name: tarceva®) or icotinib (trade name: conmana®)